Abstract
Xerostomia represents a significant sequela of combined chemoradiation for head and neck cancer. Target volumes often overlap with the parotid glands, resulting in difficulty in achieving adequate coverage or meeting dose constraints. At our institution, induction chemotherapy (IC) has been shown to decrease tumor and nodal size prior to administering concurrent chemoradiation (CCRT). One potential benefit of target volume reduction is to minimize the parotid dose and improve long-term xerostomia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology, Biology, Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
